4.4 Article

Lipid Effects of Psychiatric Medications

期刊

CURRENT ATHEROSCLEROSIS REPORTS
卷 15, 期 1, 页码 -

出版社

CURRENT MEDICINE GROUP
DOI: 10.1007/s11883-012-0292-6

关键词

First generation antipsychotic agents; Second generation antipsychotic agents; Antidepressive agents; Dyslipidemia; Lipid profiles; Monitoring

资金

  1. MSD K. K.
  2. Asahal Kasel Pharma Cooperation
  3. Astellas Pharma Inc.
  4. Eisai Co., Ltd.
  5. Otsuka Pharmaceutical Co., Ltd.
  6. Ono Pharmaceutical Co., Ltd.
  7. GlaxoSmithKline K. K.
  8. Shionogi Co., Ltd.
  9. Daiichi Sankyo Co., Ltd.
  10. Dainippon Sumitomo Pharma Co., Ltd.
  11. Mitsubishi Tanabe Pharma Corporation
  12. Eli Lilly Japan K. K.
  13. Pfizer Japan Inc.
  14. Meiji Seika Pharma Co., Ltd.
  15. Mochida Pharmaceutical Co., Ltd.
  16. Janssen Pharmaceutical K. K.
  17. Yoshitomiyakuhin Corp.
  18. Takeda Pharmaceutical Co., Ltd.
  19. Chugai Pharmaceutical Co., Ltd.
  20. Kyowa Hakko Kirin Co., Ltd.
  21. Novartis Pharma K. K.
  22. Abbott Japan Co., Ltd.
  23. Tsumura Co.

向作者/读者索取更多资源

People with schizophrenia have higher rates of medical illness and mortality than the general population. Cardiovascular disease is a major contributor to premature death in patients with schizophrenia. There has been an increase literature discussing the high prevalence of dyslipidemia, which is one of risk factors for cardiovascular disease, induced by second generation antipsychotic agents. Depression is associated with increased risks of diabetes, hypertension, cardiovascular disease. However, those may not be secondary to the use of antidepressant agents. In order to reduce the risk of cardiovascular disease in patients with schizophrenia receiving antipsychotic agents, obtaining fasting lipid measurements at regular intervals is needed. Further investigations are needed to evaluate the effects of antidepressive agents on lipid profiles.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据